[Effect of the new antimigraine drug serotonin receptor antagonist tropoxin on platelet aggregation].
The effect of the new antimigraine drug tropoxin - the serotonin receptor (5-HT2) antagonist - on the human platelet aggregation in vitro induced by ADP (1 x 10(-5) M) and epinephrine (2.5 x 10(-6) M) was studied. Tropoxin reliably inhibited the ADP-induced platelet aggregation in a concentration range of 0.01 - 7 mg/ml. A significant inhibition effect with respect to the epinephrine-induced platelet aggregation was observed in a drug concentration range of 2 - 7 mg/ml, although a reliable antiaggregant activity was also observed below 2 mg/ml. A bolus administration of tropoxin (10 mg/kg) in rabbits decreased the ADP-induced platelet aggregation ex vivo by a factor of 1.2 - 1.4. The effect appeared 45 min after treatment and was observed during subsequent 30 min.
Vasil'eva
T M
TM
Petrukhina
G N
GN
Miftakhova
N T
NT
Makarov
V A
VA
Gan'shina
T S
TS
Bezhanian
S G
SG
Mirzoian
R S
RS
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D001372:Aza Compounds / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy; D010974:Platelet Aggregation / Q000187:drug effects*; D011817:Rabbits; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
C114333:3-(3,4,5-trimethoxybenzoyloximino)-8-methyl-8-azabicyclo(3,2,1)octane; D001372:Aza Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D012702:Serotonin Antagonists; D000244:Adenosine Diphosphate; D004837:Epinephrine